Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Soft Tissues: Extraskeletal osteosarcoma

Written2013-12Andreas F Mavrogenis, Panayiotis J Papagelopoulos
First Department of Orthopaedics, Athens University Medical School, 41 Ventouri Street, 15562 Holargos, Athens, Greece

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C470-C476,C478-C479,C490-C496,C498-C499 CONNECTIVE & SOFT TISSUE
ICD-Morpho 9180/3 Extraskeletal osteosarcoma
Atlas_Id 5200
Phylum Soft Tissues::Extraskeletal osteosarcoma
Other namesSoft tissue osteosarcoma
Note Extraskeletal osteosarcoma is a high-grade malignant mesenchymal soft tissue neoplasm composed of neoplastic cells (osteoblastic, chondroblastic and fibroblastic) that produce osteoid, neoplastic bone or chondroid matrix and has a clinically aggressive course. For a lesion to be defined as extraskeletal osteosarcoma, it must arise in the soft tissue and not attached to bone or periosteum, have a uniform sarcomatous pattern, and produce osteoid and/or cartilage matrix. In contrast to the more common osteogenic sarcoma (osteosarcoma), extraskeletal osteosarcoma is a rare tumor occurring mainly in adults. Often it arises at the site of prior radiation therapy. Response to treatments (mainly chemotherapy) is worse and prognosis is much poorer compared to that for primary osteosarcoma of bone.

Clinics and Pathology

Epidemiology Extraskeletal osteosarcoma accounts for 1% to 2% of all soft tissue sarcomas and approximately 2% to 4% of all osteosarcomas. It typically affects patients between 50 and 70 years of age. The reported male to female ratio is 1.9:1.
Clinics Most extraskeletal osteosarcomas are deep seated; <10% are superficial, originating in the dermis or subcutis. The most common location is the lower extremity (75%; thigh and buttock), followed by the upper extremity (15%-23%, shoulder girdle), and the retroperitoneum (17%). A progressively enlarging soft tissue mass, rarely causing pain or tenderness is the most common clinical presentation.

Imaging
Plain radiographs, CT and MRI usually reveal a large deep-seated soft tissue mass with variable mineralization. By definition, extraskeletal osteosarcomas arise in the soft tissue and are not attached to bone or periosteum; however, they may secondarily involve the periosteum, cortex or medullary canal.
- Radiography: Shows a mass, possibly with peripheral, chunky or linear and mature calcification similar to mature bone or heterotopic ossification.
- Computed tomography: Shows a mass with ossified rim. The mass is close to the bone but not attached to it; a soft tissue mass is interposed between the bone and the ossified mass.
- MR imaging: The unmineralized portion of the tumor shows heterogeneous and relatively hypointense signal intensity on T1-weighted images and hyperintense signal intensity on T2.
- Scintigraphy: Shows intense accumulation of radioactivity in the tumor.
- Angiography: May show hypervascularity of the tumor.

 
Figure 1. Axial T1-weighted (left) and coronal T2-weighted fat suppression (right) MR imaging show a large soft tissue mass in the postero-medial thigh. The tumor is not attached to bone. Figure 2. Tumor specimen of an extraskeletal osteosarcoma.
Pathology Pathogenesis unknown. The majority develops de novo; in approximately 10% extraskeletal osteosarcomas may be radiation induced.

Gross pathology: Extraskeletal osteosarcomas may grow up to 50 cm (mean, 8-10 cm). Macroscopically, the tumors are hemorrhagic and focally necrotic, and firmly attached to the fascia without attachment to the skeleton; rarely, it may lie in contact with the periosteum; >30% appear grossly encapsulated, and >10% may exhibit extensive haemorrhagic cystic changes. A tough connective tissue capsule usually surrounds the tumors and adheres to the surrounding structures, making dissection difficult. The tumor has a remarkable ability to infiltrate the surrounding tissues; occasionally it can be confined to the subcutis or dermis, or ulcerate the overlying skin. Invasion of blood vessels is not common.

Micro pathology: Extraskeletal osteosarcoma is characterized by anaplastic sprindle cell proliferation with the presence of osteoid matrix or immature bone formed by the neoplastic cells. The tumor cells are spindle or polyhedral with cytological atypia, malignant chondroid areas, extensive areas of necrosis, mitotic activity (>10 mitoses per 10 high-power fields), and atypical mitotic figures.

All the major subtypes of osteosarcoma of bone have been reported in extraskeletal osteosarcoma. Common to all variants is the presence of neoplastic bone deposited in a lacy, trabecular or sheet-like pattern. In contrast to myositis ossificans the bone is usually most prominent in the centre of the tumor.
- Osteoblastic extraskeletal osteosarcoma: the most common variant; the tumor cells resemble malignant osteoblasts. Bone matrix is abundant.
- Fibroblastic extraskeletal osteosarcoma: the second in frequency; the tumor cell are spindle cells arranged in a herringbone or storiform pattern.
- Chondroid extraskeletal osteosarcoma: malignant cartilage predominates in the tumor matrix.
- Telangiectatic extraskeletal osteosarcoma: it contains numerous large blood filled spaces lined by malignant cells.
- Small cell extraskeletal osteosarcoma: the tumor cells are arranged in sheets of small round cells that mimic Ewing's sarcoma or lymphoma.
- Well differentiated extraskeletal osteosarcoma: rare variant; it contains abundant bone deposited in well formed trabeculae, surrounded by a minimally atypical spindle cell component similar to parosteal osteosarcoma.

Immunohistochemistry: Several studies indicate that the immunophenotype of extraskeletal osteosarcoma is similar to osteosarcoma of bone; CD99 is expressed in all types of osteosarcoma; stain for ALP is positive with a very strong reaction; osteocalcin is the most specific antigen for extraskeletal osteosarcomas expressed in the malignant cells and matrix in 82% and 75% of cases, respectively. Extraskeletal osteosarcomas are uniformly positive for vimentin, 68% express smooth muscle actin, 25% desmin, 20% S100 protein, 52% EMA, 8% keratin, and 0% PLAP. The stain for the Ki-67 analogous MIB-1 shows high proliferative activity with values around 25%.

Differential diagnosis: Myositis ossificans; Synovial and epithelioid sarcoma; Extraskeletal chondrosarcoma; Malignant fibrous histiocytoma; Rhabdomyosarcoma; Hamartoma; Malignant schwannoma; Malignant mesenchymoma; Liposarcoma with metaplastic bone.

 
Figure 3. Low power histological sections show calcified bone trabeculae and osteoid elaborated by malignant cells (Stain, hematoxylin and eosin; original magnification, 40x). Figure 4. High power histological sections shows pleomorphic malignant cells with extracellular matrix production (Stain, hematoxylin and eosin; original magnification, 200x).
Cytogenetics Systematic genetic differences between extraskeletal and bone osteosarcomas have not been documented. Three cases with clonal chromosomal aberrations have been reported; two tumors showed highly complex aberration patterns, whereas the third showed a moderately hyperdiploid karyotype with relatively few chromosomal abnormalities.
Treatment Wide margin surgical resection is the treatment of choice for extraskeletal osteosarcoma. Resection can be with amputation of limb salvage surgery if microscopically negative margins can be achieved. Adjuvant chemotherapy and/or preoperative radiation therapy may be useful, although extraskeletal osteosarcoma seems relatively chemoresistant compared to osseous osteosarcomas. Radiation may be delivered by external beam, intraoperative, and brachytherapy. Given the high grade malignant tumor and poor prognosis, aggressive treatment with preoperative radiation therapy and surgical resection for local tumor control, and (neo-)adjuvant multi-agent chemotherapy to improve survival are current treatments of choice for the patients with extraskeletal osteosarcomas. Aggressive thoracotomy and resection of the pulmonary metastases may be necessary in patients with lung metastases.
Note: The role of (neo-)adjuvant chemotherapy or radiation therapy is controversial. Disease-specific clinical trials are required to improve the outcome of these patients.
Prognosis The prognosis of the patients with extraskeletal osteosarcoma is poor; the 5-year survival ranges from 10% to 46%. More than 50% of the patients experience multiple local recurrences and distal metastases. Distal metastases are usually to the lungs (>80%), followed by the regional lymph nodes, bone, brain, liver and skin.
Note: Reported factors associated with a better outcome include size <5 cm (the most important), fibroblastic or chondroblastic histological subtype, and diminished proliferative activity as measured by Ki-67 index. However, the validity of these prognostic factors has not been confirmed in large studies. The well differentiated variant may behave in a more indolent manner; however, too few cases have been reported to draw definitive conclusions regarding their biologic potential.

Bibliography

Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases.
Bane BL, Evans HL, Ro JY, Carrasco CH, Grignon DJ, Benjamin RS, Ayala AG.
Cancer. 1990 Jun 15;65(12):2762-70.
PMID 2160317
 
18F-FDG PET/CT in a rare malignant extraskeletal osteosarcoma.
Cao Q, Lu M, Huebner T, Dilsizian V, Chen W.
Clin Nucl Med. 2013 Sep;38(9):e367-9. doi: 10.1097/RLU.0b013e3182868ace.
PMID 23856822
 
Immunophenotypic heterogeneity in osteosarcomas.
Hasegawa T, Hirose T, Kudo E, Hizawa K, Usui M, Ishii S.
Hum Pathol. 1991 Jun;22(6):583-90.
PMID 1864588
 
SPECT/CT imaging of retroperitoneal extraskeletal osteosarcoma.
Hu B, Liu Y, Cheng L, Li W, Cao X.
Clin Nucl Med. 2014 Feb;39(2):200-2. doi: 10.1097/RLU.0000000000000309.
PMID 24300353
 
Contralateral referred pain in a patient with intramedullary spinal cord metastasis from extraskeletal small cell osteosarcoma.
Kang K, Lee JH, Kim HG.
J Spinal Cord Med. 2013 Nov;36(6):695-9. doi: 10.1179/2045772312Y.0000000087. Epub 2013 Apr 12.
PMID 24090113
 
A review of 40 patients with extraskeletal osteosarcoma.
Lee JS, Fetsch JF, Wasdhal DA, Lee BP, Pritchard DJ, Nascimento AG.
Cancer. 1995 Dec 1;76(11):2253-9.
PMID 8635029
 
Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases.
Lidang Jensen M, Schumacher B, Myhre Jensen O, Steen Nielsen O, Keller J.
Am J Surg Pathol. 1998 May;22(5):588-94.
PMID 9591729
 
Primary cutaneous osteosarcoma of the skin: a report of 2 cases with emphasis on the differential diagnoses.
Llamas-Velasco M, Rutten A, Requena L, Mentzel T.
Am J Dermatopathol. 2013 Aug;35(6):e106-13. doi: 10.1097/DAD.0b013e31827f0a6f.
PMID 23503316
 
Extra-osseous osteosarcoma: a clinical and histopathological study of four cases.
Lorentzon R, Larsson SE, Boquist L.
J Bone Joint Surg Br. 1979 May;61-B(2):205-8.
PMID 285933
 
Characteristic karyotypic anomalies identify subtypes of malignant fibrous histiocytoma.
Mandahl N, Heim S, Willen H, Rydholm A, Eneroth M, Nilbert M, Kreicbergs A, Mitelman F.
Genes Chromosomes Cancer. 1989 Sep;1(1):9-14.
PMID 2562116
 
Extraskeletal osteosarcoma: a case report.
Mavrogenis AF, Papadogeorgou E, Papagelopoulos PJ.
Acta Orthop Traumatol Turc. 2012;46(3):215-9.
PMID 22659628
 
Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.
Mertens F, Fletcher CD, Dal Cin P, De Wever I, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van den Berghe H, Vanni R, Willen H.
Genes Chromosomes Cancer. 1998 May;22(1):16-25.
PMID 9591630
 
Cytogenetic aberrations and DNA ploidy in soft tissue sarcoma. A Southwest Oncology Group Study.
Mohamed AN, Zalupski MM, Ryan JR, Koppitch F, Balcerzak S, Kempf R, Wolman SR.
Cancer Genet Cytogenet. 1997 Nov;99(1):45-53.
PMID 9352795
 
Extraskeletal osteosarcoma.
Rosenberg AE, Heim S.
In: Fletcher CDM, Unni KK, Mertens F (Eds), World Health Organization classification of tumours of soft tissue and bone. Pathology and Genetics of Tumours of Soft Tissue and Bone, IARC Press, Lyon: 35-7, 2002.
 
Extraosseous osteogenic sarcoma. A review of 48 patients.
Sordillo PP, Hajdu SI, Magill GB, Golbey RB.
Cancer. 1983 Feb 15;51(4):727-34.
PMID 6571801
 
Extraskeletal osteosarcoma of the hand.
Tan KT, Idowu OK, Chandrasekar CR, Yin Q, Helliwell TR.
Hand (N Y). 2012 Mar;7(1):124-6. doi: 10.1007/s11552-011-9371-3. Epub 2011 Nov 4.
PMID 23450980
 
Well-differentiated extraskeletal osteosarcoma. A soft-tissue homologue of parosteal osteosarcoma.
Yi ES, Shmookler BM, Malawer MM, Sweet DE.
Arch Pathol Lab Med. 1991 Sep;115(9):906-9. (REVIEW)
PMID 1929787
 

Citation

This paper should be referenced as such :
Mavrogenis, AF ; Papagelopoulos, PJ
Soft Tissue Tumors: Extraskeletal osteosarcoma
Atlas Genet Cytogenet Oncol Haematol. 2014;18(6):443-446.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Tumors/ExtraskeletalOsteosarcID5200.html


External links

arrayMap Topo ( C47,C49) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseSoft Tissues: Extraskeletal osteosarcoma
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sat Jun 17 12:10:25 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.